Al-Batran S-E et al. Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK. ASCO 2022;Abstract 4003.
Botta GP et al. Multicenter phase Ib trial in the U.S. of salvage CT041 CLDN18.2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric and pancreatic adenocarcinoma. ASCO 2022;Abstract 2538.
Catenacci DVT et al. FIGHT: A randomized, double-blind, placebo-controlled, phase 2 study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2B+ advanced gastric/gastroesophageal junction adenocarcinoma (GC) (NCT03694522). ASCO 2021;Abstract 4010.
Chao J et al Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol 2021;7(6):895-902. Abstract
Doki Y et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 2022;386(5):449-62. Abstract
Feng Y et al. HER2-overexpression/amplification and survival in patients with resectable esophageal/gastroesophageal junction adenocarcinoma (E/GEJ-AC) treated with neoadjuvant carboplatin/paclitaxel-based chemoradiation. Gastrointestinal Cancers Symposium 2021;Abstract 239.
Fuchs CS et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomized, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383(9911):31-9. Abstract
Hoffman R et al. Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients. ASCO 2022;Abstract 7003.
Janjigian YY et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 2021;398(10294):27-40. Abstract
Janjigian YY et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600(7890):727-30. Abstract
Jin Z et al. Narrative review of pembrolizumab for the treatment of esophageal cancer: Evidence and outlook. Ann Transl Med 2021;9(14):1189. Abstract
Kankeu Fonkuoa LA, Yoon HH. Rapidly evolving treatment landscape for metastatic esophagogastric carcinoma: Review of recent data. Onco Targets Ther 2021;14:4361-81. Abstract
Kankeu Fonkuoa LA et al. Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma. Int J Cancer 2021;149(2):378-86. Abstract
Kawazoe A et al. Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: An open-label, single-arm, phase 2 trial. Lancet Gastroenterol Hepatol 2021;6(3):209-17. Abstract
Kelly RJ et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. New Engl J Med 2021;384(13):1191-203. Abstract
Kelly RJ et al. Adjuvant nivolumab (nivo) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577. ASCO 2021;Abstract 4003.
Lorenzen S et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel – Results from the phase II RAMIRIS study of the German Gastric Center Study Group at AIO. Eur J Cancer 2022;165:48-57. Abstract
Luo H et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial. JAMA 2021;326(10):916-25. Abstract
Mesa RA et al. MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. ASCO 2022;Abstract 7002.
Metges J-P et al. First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the Phase 3 KEYNOTE-590 study. Gastrointestinal Cancers Symposium 2022;Abstract 241.
Sahin U et al. FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 2021;32(5):609-19. Abstract
Shen L et al. Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase 3 ORIENT-15 study. ESMO 2021;Abstract LBA52.
Shitara K et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018;19(11):1437-48. Abstract
Shitara K et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 2022;603(7903):942-8. Abstract
Sun J et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet 2021;398(10302):759-71. Abstract
Van Cutsem E et al. Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. ESMO 2021;Abstract LBA55.
Walden D et al. Maintenance therapy in first-line gastric and gastroesophageal junction adenocarcinoma: A retrospective analysis. Front Oncol 2021;11:641044. Abstract
Wang Z-X et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell 2022;40(3):277-88.e3. Abstract
Wilke H et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trail. Lancet Oncol 2014;15(11):1224-35. Abstract
Xu R-H et al. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): A randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2021;6(12):1015-24. Abstract
Xu J et al. Sintilimab plus chemotherapy (chemo) versus chemo as the first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16). ESMO 2021;Abstract LBA53.
Yamaguchi K et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized multicenter, open-label, phase 2 study (DESTINY-Gastric01). Gastrointestinal Cancers Symposium 2022;Abstract 242.
Yoon HH. Ramucirumab plus paclitaxel for gastric cancer in China. Lancet Gastroenterol Hepatol 2021;6(12):975-6. Abstract
Yoon HH et al. Association of magnitude and consistency of PD-L1 expression and other variables associated with benefit from immune checkpoint inhibition (ICI): Systematic review and meta-analysis of 14 phase 3 trials in advanced gastroesophageal cancer (GEC). ASCO 2022;Abstract 344.
Zhu M et al. Trifluridine/tipiracil plus ramucirumab in gastric cancer. Lancet Gastroenterol Hepatol 2021;6(3):154-5. Abstract
Zhu M et al. Understanding suboptimal response to immune checkpoint inhibitors. Adv Biol (Weinh) 2022;[Online ahead of print]. Abstract